Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs KraneShares CSI China Internet ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while KraneShares CSI China Internet ETF trades at $26.26. Which is the better fit depends on your goals.
| ALNY | KWEB | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $42.94 |
52-Week Low | $278.09 | $23.63 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
KWEB trades at $26.38, down 0.38% on the day, with technical indicators showing mixed signals - bullish moving averages but neutral oscillators. The ETF offers concentrated exposure to Chinese internet and AI companies, currently trading near 52-week lows according to Seeking Alpha analysis from June 29, 2026. Recent news highlights China's significant AI infrastructure investments and strong export performance, providing potential catalysts for the underlying holdings.
The ETF presents a value opportunity with Chinese tech stocks trading at discounts to Western peers, though geopolitical tensions and regulatory risks remain concerns. AI-driven growth and government support for technology sectors offer upside potential, but investors face China-specific market volatility and US-China trade friction risks that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
